GREENWICH LIFESCIENCES, INC. Net Income (Loss) Available to Common Stockholders, Basic
GREENWICH LIFESCIENCES, INC. (GLSI) reported Net Income (Loss) Available to Common Stockholders, Basic of -$9.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-11
- GREENWICH LIFESCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$3.95M.
- GREENWICH LIFESCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$5.66M.
- GREENWICH LIFESCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$4.94M.
- GREENWICH LIFESCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was -$3.75M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$3.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$9.61M 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | -$5.66M 10-Q · filed 2026-06-04 | ||||
| 2025-09-30 | -$4.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$8.69M derived: sum of 2 quarters · filed 2026-08-11 | -$11.44M 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | -$3.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$6.49M 10-Q · filed 2026-08-11 | -$7.28M 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | -$2.74M 10-Q · filed 2026-06-04 | -$3.26M 10-Q · filed 2025-05-20 | |||
| 2024-09-30 | -$2.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$5.28M derived: sum of 2 quarters · filed 2025-11-14 | -$7.75M 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | -$2.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$5.08M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$2.47M 10-Q · filed 2025-05-20 | ||||
| 2023-09-30 | -$2.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$4.02M derived: sum of 2 quarters · filed 2024-11-14 | -$6.15M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | -$1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$3.75M 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$2.12M 10-Q · filed 2024-05-20 | ||||
| 2022-09-30 | -$2.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$3.07M derived: sum of 2 quarters · filed 2022-11-14 | -$5.03M 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | -$746.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$2.72M 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | -$1.97M 10-Q · filed 2023-05-22 | ||||
| 2021-09-30 | -$863.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$1.61M derived: sum of 2 quarters · filed 2022-11-14 | -$2.21M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$749.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$1.35M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | -$597.01K 10-Q · filed 2022-05-20 | ||||
| 2020-09-30 | -$256.87K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$467.30K derived: sum of 2 quarters · filed 2021-11-15 | -$711.94K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$210.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$455.07K 10-Q · filed 2021-08-13 | |||
| 2020-03-31 | -$244.64K 10-Q · filed 2021-05-20 | ||||
| 2019-09-30 | -$3.09M 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |